# EDGAR Filing Document

**Accession Number:** 0001351172
**File Stem:** 0000950170-23-000971
**Filing Date:** 2023-1
**Character Count:** 5433
**Document Hash:** 3324945a404eea41a43c180ddbc4c34e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-000971.hdr.sgml**: 20230120

**ACCESSION NUMBER**: 0000950170-23-000971

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230120

**FILED AS OF DATE**: 20230120

**DATE AS OF CHANGE**: 20230120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Liminal BioSciences Inc.
- **CENTRAL INDEX KEY:** 0001351172
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39131
- **FILM NUMBER:** 23540967

**BUSINESS ADDRESS:**
- **STREET 1:** 231 DUNDAS STREET EAST
- **CITY:** BELLEVILLE
- **STATE:** A6
- **ZIP:** K8N 1E2
- **BUSINESS PHONE:** 450-781-0115

**MAIL ADDRESS:**
- **STREET 1:** 440 ARMAND-FRAPPIER BLVD.
- **STREET 2:** SUITE 300
- **CITY:** LAVAL
- **STATE:** A8
- **ZIP:** H7V 4B4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ProMetic Life Sciences Inc
- **DATE OF NAME CHANGE:** 20060126

**UNITED STATES SECURITIES**

**AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the Month of January 2023**

**Commission File Number: 001-39131**

**LIMINAL BIOSCIENCES INC.**

**(Translation of registrant's name into English)**

------

**440 Armand-Frappier Boulevard, Suite 300**

**Laval, Québec**

**H7V 4B4**

**(Address of principal executive office)**

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: ☒ Form 20-F ☐ Form 40-F

------

**<u>INCORPORATION BY REFERENCE</u>**

This Report on Form 6-K (the "Report") and Exhibit 99.1 to this Report are hereby expressly incorporated by reference into the registrant's registration statements on Form F-3 (File nos. 333-251055, 333-245703 and 333-251065) filed with the Securities and Exchange Commission on December 1, 2020, December 2, 2020 and December 2, 2020, respectively, and the registration statement on Form S-8 (File no. 333-235692) filed with the Securities and Exchange Commission on December 23, 2019.

**<u>EXHIBIT LIST</u>**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [<u>Report of Voting Results following the Special Meeting of the Shareholders held on January 20, 2023</u>](lmnl-ex99_1.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** |
| Date: January 20, 2023 | By: | /s/ Bruce Pritchard | /s/ Bruce Pritchard |
|  |  | Name | Bruce Pritchard |
|  |  | Title: | Chief Executive Officer |

---

------

## Exhibit 99.1

![img164290822_0.jpg](img164290822_0.jpg)

**EXHIBIT 99.1**

**<u>VIA SEDAR</u>**

January 20, 2023

Alberta Securities Commission

Autorité des marchés financiers (Québec)

British Columbia Securities Commission

Manitoba Securities Commission

New Brunswick Securities Commission

Service Newfoundland and Labrador

Nova Scotia Securities Commission

Ontario Securities Commission

Prince Edward Island Securities Office

Saskatchewan Financial Services Commission

Re: Report of Voting Results pursuant to Section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations (« **NI 51-102** »)

Following the Special Meeting of Shareholders of Liminal BioSciences Inc. (the "**Company**") held virtually on January 20, 2023 (the "**Meeting**"), and in accordance with section 11.3 of NI 51-102, continuous disclosure obligations, we hereby advise you of the matters voted upon at the Meeting and the voting results, the whole as detailed in the Management Information Circular of the Company dated December 12, 2022 (the "**Circular**"). According to the scrutineers' report, the shareholders present at the meeting, in person or by proxy, represented 22,694,417 common Shares, or 73.11% of the 31,042,560 common shares outstanding on December 5, 2022, the record date for the Meeting.

**Share Consolidation of the Outstanding Common Shares of the Company**

The amendment to the articles of the Company to effect a consolidation of all of the issued and outstanding common shares of the Company was approved pursuant to a vote conducted by ballot, on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share, effective as at the discretion of the Board, provided that effective date shall be before December 31, 2023.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**For** | &nbsp;&nbsp;**For** | &nbsp;&nbsp;**Against** | &nbsp;&nbsp;**Against** |
| &nbsp;&nbsp;Votes | &nbsp;&nbsp;% | &nbsp;&nbsp;Votes | &nbsp;&nbsp;% |
| &nbsp;&nbsp;22438719 | &nbsp;&nbsp;98.88 | &nbsp;&nbsp;254672 | &nbsp;&nbsp;1.12 |

---

**Liminal BioSciences Inc.**

(s) Marie Iskra

Marie Iskra

General Counsel & Secretary

www.liminalbiosciences.com info@liminalbiosciences.com +1.450.781.0115 Liminal BioSciences inc.440 Boul. Armand-Frappier, Suite 300 Laval, Québec,H7V4B4, Canada

------